
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion Inc. is advancing its clinical-stage pipeline, particularly with its lead candidate icovamenib, which has shown significant reductions in HbA1c levels in Type 2 diabetes patients over 52 weeks, indicating potential for long-term disease modification. The company is also progressing BMF-650, an oral GLP-1 receptor agonist that demonstrated promising preclinical weight reduction and glycemic control results, signaling a strong therapeutic potential for obesity and diabetes management. Furthermore, Biomea Fusion has made strides in capitalizing its pipeline through a proposed equity and warrant offering, while reducing its net loss significantly from $32.8 million in Q3 2024 to $16.4 million in Q3 2025, underscoring improved financial health.
Bears say
Biomea Fusion Inc has shown a significant reduction in research and development (R&D) expenses, dropping from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, which may suggest operational inefficiencies or reduced investment in critical areas for product development. General and administrative (G&A) expenses also declined from $6.8 million to $4.2 million, further indicating cost-cutting measures that may not align with growth expectations. Additionally, the company's price target was lowered due to changes in the share count, reflecting a potentially negative adjustment in market sentiment regarding the company's valuation.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares